Shopping Cart
- Remove All
Your shopping cart is currently empty
Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $198 | In Stock | |
| 5 mg | $619 | In Stock | |
| 10 mg | $993 | In Stock | |
| 25 mg | $1,470 | In Stock | |
| 50 mg | $1,980 | In Stock |
| Description | Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications. |
| Synonyms | CC-95251, CC95251, BMS-986351, BMS986351 |
| Cas No. | 2543693-10-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.